Helus Pharma Gains Veteran Outreach Via TARA Mind Partnership
Event summary
- Helus Pharma has partnered with TARA Mind and VETS to support recruitment for its Phase 3 PARADIGM HLP003 clinical trial for Major Depressive Disorder (MDD).
- The collaboration is intended to expand mental health awareness and access within the veteran community.
- The partnership is directly linked to President Trump’s April 18, 2026 Executive Order focused on accelerating mental health treatment research.
- HLP003 is an FDA Breakthrough Therapy-designated NSA (novel serotonergic agonist).
The big picture
This partnership highlights the growing recognition of the unmet mental health needs within the veteran community and the increasing pressure on pharmaceutical companies to address these needs, particularly given government incentives. The collaboration leverages a niche organization, TARA Mind, which may offer a cost-effective alternative to traditional recruitment methods. Helus Pharma's reliance on Executive Orders for strategic advantage introduces a degree of political risk.
What we're watching
- Recruitment Success
- The efficacy of this partnership in accelerating Phase 3 recruitment for HLP003 will be a key indicator of its value, given the challenges of clinical trial enrollment.
- Executive Order Impact
- The long-term influence of the Executive Order on Helus Pharma’s ability to access veteran populations and secure favorable regulatory pathways warrants monitoring.
- Commercialization Risk
- The success of Helus Pharma's NSA platform hinges on securing regulatory approvals and demonstrating durable efficacy, which remains a significant risk despite the Breakthrough Therapy designation.
Related topics